Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 2, 2009, Pages 137-144

  D'Annunzio, Verónica ^a   Donato, Martín ^a   Erni, Lukas ^a   Miksztowicz, Verónica ^a   Buchholz, Bruno ^a   Carrión, Cristina Lorenzo ^a   Schreier, Laura ^a   Wikinski, Regina ^a   Gelpi, Ricardo J ^a   Berg, Gabriela ^a   Basso, Nidia ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Matrix metalloproteinases; Myocardial infarction; Statins

Indexed keywords

DOXYCYCLINE; GELATINASE A; ROSUVASTATIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE FUNCTION; HYPERCHOLESTEROLEMIA; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; RABBIT; ANIMAL; DRUG ANTAGONISM; HEART INFARCTION; HEART MUSCLE; METABOLISM; PATHOLOGY; REPERFUSION INJURY;

ANIMALS; DOXYCYCLINE; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MATRIX METALLOPROTEINASE 2; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PYRIMIDINES; RABBITS; SULFONAMIDES;

EID: 65549166707     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318197c5e9     Document Type: Article

References (40)

1. Pearson TA. Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins. Am J Cardiol. 1998;82:28S-30S.
2. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996;156:2085-2092. (Pubitemid 26346967)
3. Mason JC. Statins and their role in vascular protection. Clin Sci (Lond). 2003;105:251-266.
4. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207-213.
5. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation. 1998;97: 1129-1135. (Pubitemid 28152885)
6. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol. 2003;41: 508-515.
7. Di Napoli P, Di Muzio M, Maggi A, et al. Simvastatin reduces postischemic coronary dysfunction: ultrastructural and functional findings after acute administration. Microvasc Res. 2000;59:181-185. (Pubitemid 30073153)
8. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 2001;49:281-287. (Pubitemid 32119545)
9. Wolfrum S, Grimm M, Heidbreder M, et al. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol. 2003;41:474-480. (Pubitemid 36255308)
10. Jones SP, Trocha SD, Lefer DJ. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol. 2001;21:2059-2064.
11. Bauersachs J, Galuppo P, Fraccarollo D, et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation. 2001;104:982-985. (Pubitemid 32803872)
12. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
13. Ikeda Y, Young L, Lefer A. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol. 2003;41:649-656. (Pubitemid 36373804)
14. Wang CS, Suarez-Pinzon W, Dyck J, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002;106:1543-11159 (Pubitemid 35050883)
15. Lalu M, Csonka C, Giricz Z, et al. Preconditioning decreases ischemia/ reperfusion-induced release and activation of matrix metalloproteinase-2. Biochem Biophys Res Commun. 2002;296:937-941.
16. Rork TH, Hadzimichalis NM, Kappil MA, et al. Acetaminophen attenuates peroxynitrite-activated matrix metalloproteinase-2-mediated troponin I cleavage in the isolated guinea pig myocardium. J Mol Cell Cardiol. 2006;40:553-561.
17. Sawicki G, Leon H, Sawicka J, et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation. 2005;112: 544-552. (Pubitemid 41060795)
18. WangW, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res. 2002;53: 165-174. (Pubitemid 34020777)
19. Maack C, Kartes T, Kilter H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation. 2003;108: 1567-1574. (Pubitemid 37187782)
20. Cheung PY, Sawicki G, Wozniak M, et al. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation. 2000; 101:1833-1839. (Pubitemid 30213106)
21. Nip LH, Uitto VJ, Golub LM. Inhibition of epithelial cell matrix metalloproteinases by tetracyclines. J Periodontal Res. 1993;28: 379-385. (Pubitemid 23282035)
22. Fert-Bober J, Sawicki G, Lopaschuk GD, et al. Proteomic analysis of cardiac metabolic enzymes in asphyxiated newborn piglets. Mol Cell Biochem. 2008;318:13-21.
23. González GE, Rodríguez M, Donato M, et al. Effects of low-calcium reperfusion and adenosine on diastolic behavior during the transitory systolic overshoot of the stunned myocardium in the rabbit. Can J Physiol Pharmacol. 2006;84:265-272. (Pubitemid 43901435)
24. Mirotsou M, Zhang Z, Deb A, et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci U S A. 2007; 104:1643-1648. (Pubitemid 46214644)
25. Fujioka D, Saito Y, Kobayashi T, et al. Reduction in myocardial ischemia/ reperfusion injury in group X secretory phospholipase A2-deficient mice. Circulation. 2008;117:2977-2985.
26. Cohen MV, Yang XM, Neumann T, et al. Favorable remodeling enhances recovery of regional myocardial function in the weeks after infarction in ischemically preconditioned hearts. Circulation. 2000;102: 579-583. (Pubitemid 30639977)
27. Ojha N, Roy S, Radtke J, et al. Characterization of the structural and functional changes in the myocardium following focal ischemiareperfusion injury. Am J Physiol Heart Circ Physiol. 2008;294: H2435-H2443.
28. Assmann G, Jabs HU, Kohnert U, et al. LDL-cholesterol determination in blood serum following precipitation of LDL with polyvinylsulfate. Clin Chim Acta. 1984;140:77-83. (Pubitemid 14113704)
29. Assmann G, Schriewer H, Schmitz G, et al. Quantification of highdensity- lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem. 1983;29:2026-2030. (Pubitemid 14203604)
30. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-275.
31. Bao N, Minatoguchi S, Kobayashi H, et al. Pravastatin reduces myocardial infarct size via increasing protein kinase C-dependent nitric oxide, decreasing oxyradicals and opening the mitochondrial adenosine triphosphate-sensitive potassium channels in rabbits. Circ J. 2007;71: 1622-1628. (Pubitemid 47529667)
32. Tiefenbacher CP, Kapitza J, Dietz V, et al. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol. 2003;285:H59-H64. (Pubitemid 36736414)
33. Satoh K, Takaguri A, Itagaki M, et al. Effects of rosuvastatin and pitavastatin on ischemia-induced myocardial stunning in dogs. Pharmacol Sci. 2008;106:593-599. (Pubitemid 351556238)
34. Donato M, D'Annunzio V, Berg G, et al. Ischemic postconditioning reduces infarct size by activation of A1 receptors and K+(ATP) channels in both normal and hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 2007;49:287-292. (Pubitemid 46855122)
35. Feigl EO. Coronary physiology. Physiol Rev. 1983;63:1-205.
36. Kwan JA, Schulze CJ, Wang W, et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J. 2004; 18:690-692.
37. Mookerjee I, Unemori EN, DU XJ, et al. Relaxin modulates fibroblast function, collagen production, and matrix metalloproteinase-2 expression by cardiac fibroblasts. Ann N Y Acad Sci. 2005;1041:190-203. (Pubitemid 41132246)
38. Giricz Z, Lalu MM, Csonka C, et al. Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase- 2 inhibition. J Pharmacol Exp Ther. 2006;316:154-161. (Pubitemid 41832592)
39. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res. 2004;61:461-470. (Pubitemid 38210152)
40. Prasan AM, McCarron HC, White MY, et al. Duration of ischaemia determines matrix metalloproteinase-2 activation in the reperfused rabbit heart. Proteomics. 2002;2:1204-1210.